Acadia Healthcare Company, Inc.

source: coverage-next-full ticker: ACHC step: "01" title: Business Model & Overview created: 2026-06-03

Step 01 — Business Model & Overview: ACHC (Acadia Healthcare Company, Inc.)

[S1] Business Model Summary

Acadia Healthcare is the largest publicly traded pure-play behavioral health facility operator in the United States. Its economic model is straightforward: own or lease inpatient psychiatric beds and outpatient program slots, staff them with licensed clinicians, and generate revenue from public and private payors (Medicaid, Medicare, commercial insurance) on a per-diem or per-service basis.

The business is capital-intensive (facilities + equipment), labor-intensive (clinicians and nursing staff ~53% of revenue), and heavily regulated (state licensing, CON laws, federal reimbursement rules). The moat sources — if durable — are geographic network density, CON barriers in select markets, brand/referral relationships with hospitals and payers, and scale in procurement and staffing.

Sources: [S1] 10-K FY2024; StockAnalysis summary (2026-06-03)

[S2] Value-Chain Layer Map

Layer                       ACHC's Role
─────────────────────────────────────────────────────────────────
DEMAND GENERATION           Referrals from hospital ERs, PCPs,
                            payers, community mental health orgs,
                            self-referrals. ACHC invests in
                            referral relationships + care coordination.

FACILITY OWNERSHIP          Own ~262 facilities (~11,850 beds).
                            Mix of owned real estate + lease.
                            Capital-intensive: Net PP&E $3.24B (FY2025).

CLINICAL SERVICE DELIVERY   ACHC employs/contracts psychiatrists,
                            psychologists, nurses, counselors,
                            behavioral health techs (~23,000 employees).
                            Service types: inpatient, PHP, IOP, MAT/CTC,
                            eating disorders, youth programs.

PAYOR CONTRACTING           Contracts with state Medicaid programs
                            (~57% of revenue), commercial MCOs (~28%),
                            Medicare (~15%). Rate negotiations are
                            recurring and material to margin.

BACK-OFFICE / ADMIN         Centralized billing, compliance, credentialing,
                            HR, supply chain from Franklin TN HQ.
                            Scale benefit: >$3B revenue creates leverage
                            vs. smaller independent operators.

Sources: [S2] 10-K FY2024 business description; proxy filings

[S3] Service Line Architecture

Inpatient Psychiatric Hospitals & Residential Treatment Centers (est. ~55-60% of revenue)

• Acute inpatient psychiatric care for adults and youth
• High-acuity, typically 7-30 day length of stay
• Highest reimbursement per day; most capacity-constrained service line
• Adding ~600-800 beds/year predominantly in this category

Comprehensive Treatment Centers / CTCs (~15-20% of revenue est.)

• Medication-Assisted Treatment (MAT) for opioid use disorder
• Outpatient model; daily buprenorphine/methadone dispensing
• Opened 9 new CTCs in FY2024; heavily Medicaid-reimbursed
• Subject to SAMHSA/DEA regulatory oversight in addition to state licensing

Partial Hospitalization (PHP) & Intensive Outpatient (IOP)

• Step-down from inpatient; 3-6 hours/day treatment
• Growing as payors push earlier discharge from inpatient settings

Eating Disorder Residential & Outpatient

• Residential (24-hour care) and day-treatment programs
• Primarily commercial insurance; higher revenue per day than general psych

Youth & Adolescent Programs

• Residential treatment centers for youth; significant Medicaid exposure
• Subject to heightened regulatory scrutiny (youth facility oversight)

Sources: [S3] 10-K FY2024; competitive landscape analysis

[S4] Revenue Model — Economic Mechanics

Core revenue equation:

Revenue = Σ (Beds × Utilization Rate × Net Revenue Per Patient Day)
         + Outpatient visits × Net Revenue Per Visit

Drivers of same-facility revenue growth (FY2024: +7.6%):

• Volume: Same-facility patient days +3.2% (admissions +1.3%, length of stay slightly up)
• Rate: Same-facility revenue per patient day +4.3% (Medicaid rate updates, commercial mix improvement)

New facility revenue contribution: Beds added in prior years ramp over 24-36 months; new facilities are dilutive to margins initially, then accretive as census fills.

Payor mix sensitivity:

• Medicaid: ~57% of revenue; state-set rates; ~70-80% of Medicare rates; highly stable volume but low rate growth
• Commercial: ~28%; best rates; MCO contracting determines net realization
• Medicare: ~15%; set by CMS; 14.6% cut to key psych CPT codes in 2025 is a headwind

Sources: [S4] 10-K FY2024 MD&A; consensus data (2026-06-03)

[S5] Growth Strategy — Five Pathways

ACHC's stated growth strategy operates through five pathways [S5]:

1. Bed additions at existing facilities — lowest cost, fastest to revenue ($300-400K/bed)
2. Joint venture partnerships — partner with health systems (risk-sharing, referral access)
3. De novo facility openings — greenfield; highest cost ($1M+/bed), 24-36 month ramp
4. Acquisitions — bolt-on; slowed significantly since 2020; FY2024 acquisition: Turning Point Centers (76 beds, $54M)
5. Continuum of care expansion — PHP/IOP alongside inpatient; CTCs in new markets

FY2024 execution: Added 776 beds total (312 expansions + 464 new openings), 9 new CTCs, 1 acquisition. FY2025 CapEx: $572M (moderated from $690M peak) FY2026 CapEx guidance: ~$450-570M (management targeting decline)

Sources: [S5] 10-K FY2024 business description; investor presentation 2024

[S6] Management & Ownership

Leadership (as of mid-2026):

• CEO: Christopher Osteen (appointed ~2025/2026, previously Kindred Healthcare); replacing Debbie Osteen (departed)
• CFO: David Dixon (base salary $690K; key continuity executive)
• Other NEOs: Farley ($550K base)

Ownership:

• Wellington Management: 12.76% (largest holder; active value investor)
• BlackRock: ~5% (passive)
• Vanguard: ~5.51% (passive, 5,079,563 shares per April 2026 13G)
• Short interest: 24.9% of float (22.6M shares) — significant bear thesis in the market
• No insider open-market buying during ~70-85% drawdown (2023-early 2026); management blackout likely due to DOJ investigation

Sources: [S6] Governance file; StockAnalysis ownership data; proxy DEF 14A 2025

[S7] Competitive Position Summary

ACHC holds the #1 pure-play US behavioral health scale position, though Universal Health Services (UHS) — a diversified hospital operator — has a larger absolute behavioral bed count. Key competitive differentiators:

• Pure-play focus: 100% behavioral health vs. UHS (behavioral is ~50% of UHS)
• Geographic breadth: 39 states provides national payor contracting leverage
• CON barriers: Licensed inpatient psych beds in CON states are effectively non-replicable

Key vulnerabilities:

• Medicaid concentration: 57% exposure creates political/budget risk
• Labor: Psychiatrist shortage is industry-wide; ACHC's scale helps but doesn't eliminate
• DOJ overhang: Civil investigation into SUD billing practices at certain facilities

Sources: [S7] Competitive landscape analysis; 10-K FY2024

Source Index

source: coverage-next-full ticker: ACHC step: "12" title: Bull vs. Bear — Catalysts & Analyst Debate created: 2026-06-03 note: Transcript analysis not performed — analyst debate inferred from consensus notes, press releases, and recent news

Step 12 — Bull vs. Bear: ACHC

Note: Earnings call transcript analysis was NOT performed (coverage-next-full path). The analyst debate below is reconstructed from analyst actions, consensus data, investor conference presentations (Leerink March 2025/2026), and SEC filings. This is a filings-and-consensus approximation of the live market debate.

[S1] The Core Analytical Debate

The market disagrees fundamentally on whether ACHC's capacity expansion program will generate returns above WACC at the portfolio level, and whether the DOJ investigation will resolve at a manageable cost or impair the equity materially. At $24.42/share (~8x FY2026E EBITDA), the market is pricing in meaningful probability that one or both tail risks materialize.

Bear thesis (short interest: 24.9%): ACHC is a leveraged, government-reimbursement-dependent facility operator burning cash during an uncertain regulatory environment. The DOJ investigation adds binary risk to a balance sheet with limited buffer. FCF turning positive by end-2026 is management's promise, not a structural certainty — if CapEx stays elevated or EBITDA disappoints, the equity is more impaired than the current price implies.

Bull thesis (Wellington 12.76%, 7-8 Buy ratings): Behavioral health demand is secular and structural; ACHC's 12,500+ licensed beds are hard to replicate (CON barriers); the discount to intrinsic value (~8x EBITDA vs. 9-11x sector) reflects known, manageable risks; and FCF inflection in 2027 will catalyze multiple expansion.

Sources: [S1] Consensus data; StockAnalysis; investor presentation 2024

[S2] Bull Catalyst Chain

Catalyst 1: FCF Inflection (Expected 2027)

• CapEx declining ($690M peak FY2024 → $572M FY2025 → guided $450-570M FY2026 → targeted <$400M FY2027)
• Adj. EBITDA stable at $590-610M/year as new beds ramp
• At $450M CapEx and $600M adj. EBITDA, normalized OCF of ~$500M would generate $50M+ FCF
• FCF positive = deleveraging begins, buyback activation possible, multiple expansion
• Timing: Management targeted "cash flow positive by end-2026" = implies FCF improvement in H2 2026; full-year FCF positive likely FY2027

Catalyst 2: DOJ Investigation Resolution

• Civil settlement announced at manageable size ($100-200M range would be digestible)
• Removes the single largest uncertainty overhanging the stock
• Short covering likely post-resolution (25% of float is short; 8 days to cover)
• Precedent: Multiple behavioral health operators have settled DOJ investigations without existential consequences

Catalyst 3: New Bed Ramp to Mature Utilization

• Beds added in FY2023-FY2025 (~2,000+ beds) are in the 24-36 month ramp phase
• As occupancy fills, revenue and EBITDA per bed improves without additional capital investment
• Same-facility revenue growth of 7-10% is achievable if payor mix holds and volume fills

Catalyst 4: Medicaid Rate Relief or Commercial Mix Improvement

• States periodically increase Medicaid behavioral health rates (ARPA funds, ARP extensions, advocacy pressure)
• MHPAEA commercial parity: even partial enforcement improvement drives higher commercial-rate admissions
• A 2pp commercial mix improvement (28% → 30%) adds ~$60-70M revenue at premium rates

Sources: [S2] Consensus data; investor presentation 2024; 10-K FY2024; industry analysis

[S3] Bear Catalyst Chain

Bear Catalyst 1: DOJ Settlement Larger Than Expected

• A $300-500M+ civil settlement would add meaningfully to debt (leverage from 4.1x toward 5x+)
• At 4.1x leverage with FCF negative, a large settlement tests covenant headroom and potentially requires equity raise at depressed prices
• Timeline uncertainty: could be 1-3+ years away, keeping stock under pressure

Bear Catalyst 2: EBITDA Shortfall from Payor Pressure

• FY2025 EBITDA ($608.9M) missed initial guidance range significantly ($675-725M)
• Headwinds: $10M Medicare cuts, $25-30M malpractice, $25-30M NY/PA Medicaid pressure
• If similar headwinds persist or worsen in FY2026, guidance of $575-610M could be at risk
• Below-guidance outcome would drive multiple compression from already-low 8x EBITDA

Bear Catalyst 3: Federal Medicaid Cuts

• Block grant / per-capita cap proposals in federal budget debates would fundamentally restructure Medicaid
• A 10% Medicaid rate reduction across ACHC's book = ~$180M revenue loss; would impair EBITDA by $80-100M at current margins
• Probability is low (politically difficult to pass) but would be existential if enacted

Bear Catalyst 4: De Novo Beds Underperform

• High-cost de novo beds (>$1M/bed) require 3+ years to reach full occupancy
• If new markets have weaker referral pipelines than existing markets, EBITDA drag could persist beyond guidance
• Labor constraints in new markets could limit census even with licensed capacity

Bear Catalyst 5: Credit Market Access Impairment

• If leverage stays elevated and FCF stays negative beyond 2027, debt markets may impose more onerous terms or require debt paydown
• A credit market disruption (2020/2023-style credit spread widening) at peak leverage would be highly damaging

Sources: [S3] Consensus data; investor presentation 2024; 10-K FY2024 risk factors; 10-K FY2023

[S4] Analyst Debate Summary

Constructive analysts (7-8 Buy):

• Raymond James ($39 target): Most bullish; sees FCF inflection + DOJ resolution as double catalyst; 25% short float = squeeze potential
• Deutsche Bank ($32 target, Buy): Comfortable with leverage trajectory; sees managed care rate environment stabilizing; values unique US behavioral market position
• RBC ($30+ target): Positive on Q1 2026 beat; models same-facility growth accelerating through 2027

Cautious/Neutral analysts (6-7 Hold):

• TD Cowen ($24-25 target, Buy but constrained): Values execution improvement but FY2026 EPS guidance of $1.30-1.55 limits near-term upside
• Barclays ($20 target, Equal Weight): Limited conviction until DOJ resolves; leveraging into uncertainty creates asymmetric downside

Negative (1-2 Sell):

• Bank of America ($13 target, Underperform): Most bearish; models DOJ settlement at $300M+; believes FCF positive timeline is too optimistic; values at 7x depressed EBITDA

Sources: [S4] Consensus data; analyst action log

Bull Case — 3 Bullets

1. FCF inflection: CapEx declining toward maintenance levels by FY2027 unlocks $200M+ annual FCF; share price re-rates from 8x to 10-12x EBITDA as the capital-allocation cycle completes
2. DOJ resolution at manageable scale: A $100-200M civil settlement removes the largest uncertainty, triggers short covering (25% float), and clarifies the capital structure trajectory
3. Bed ramp economics: 2,000+ beds added FY2023-FY2025 mature toward full utilization, driving 7-10% same-facility revenue growth without incremental capital — EBITDA to $700M+ by FY2028

Bear Case — 3 Bullets

1. DOJ settlement exceeds expectations: A $300-500M settlement at peak leverage (4x+) forces dilutive equity issuance or covenant breach, erasing the equity value cushion above debt
2. Medicaid policy shock: Federal block grant or state budget cuts reduce the 57%-Medicaid revenue base by 5-10%; EBITDA declines $100-175M; deleveraging becomes impossible and stock returns to $10-15
3. FCF never inflects: De novo beds ramp slowly; labor costs remain elevated; CapEx targets slip; by 2027 leverage is 4.5x+ and the management credibility deficit drives permanent multiple discount vs. UHS

Sources: [S4] Consensus data; analyst debate synthesis; Steps 11-12

Source Index